Trial Profile

An Open-label Phase II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ABSK043 in Combination With Glecirasib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring a KRAS G12C Mutation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Nov 2025 According to an Abbisko Therapeutics media release, this study obtained Investigational New Drug approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) in August 2025. This successful first patient dosing marks a significant step forward in the development of this promising combination regimen.
03 Nov 2025 Status changed from not yet recruiting to recruiting, according to an Abbisko Therapeutics media release.
17 Sep 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com